Leal Therapeutics focuses on developing neuro-metabolic treatments for high-need central nervous system disorders and was launched in 2021. Its lead program, LTX-001, is a brain-penetrant oral GLS1 inhibitor that completed single and multiple ascending dose Phase 1 trials and has initiated a Phase 1b/2a trial in adults with schizophrenia with initial data expected by year-end. A second program, LTX-002, is an intrathecally delivered antisense oligonucleotide targeting SPTLC1 and is being evaluated in the NeurALS Phase 1/2 trial in adults with ALS. The company also is developing a next-generation CNS delivery platform using antibody-like shuttle technology to enable transport of peripherally administered therapeutics to the brain. Leal states it has capabilities to develop and produce both small molecule and nucleic acid CNS therapeutics. The recent Series A second close of $30 million, which added Eli Lilly to its investor syndicate, is intended to support clinical milestones for LTX-001 and additional dosing cohorts for LTX-002.

Total raised

$144M

Funding rounds

4

Latest round

Series A

Latest activity

Aug 2026